Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Oct 4, 2024
Product Development

I-SPY 2.2 is working. Why aren’t others replicating the design?

Initial data show the I-SPY 2.2 design can uncover less toxic neoadjuvant breast cancer therapies
BioCentury | Mar 17, 2022
Management Tracks

Denali co-founder, COO Schuth to take on CFO role

Plus Immunic promotes Whaley to CFO and updates from Mablink, Agendia, SNIPR and more
BioCentury | Jan 21, 2022
Deals

Illumina deal takes Agendia’s tests directly to hospitals 

Partners to develop new tests for breast cancer as part of push to decentralize NGS testing
BioCentury | Jul 13, 2017
Company News

ASCO recommends MammaPrint to inform chemo use

BioCentury | Jul 10, 2017
Company News

ASCO recommends MammaPrint to inform chemo use

BioCentury | Sep 5, 2016
Clinical News

MammaPrint: Phase III data

BioCentury | Mar 9, 2015
Clinical News

MammaPrint FFPE regulatory update

BioCentury | Jan 27, 2015
Politics & Policy

CMS to discuss prognostic tests for cancer

BioCentury | Apr 28, 2014
Product Development

Not so negative

Why Puma still sees role for neratinib in HER2-negative breast cancer
Items per page:
1 - 10 of 65